Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.

Journal of the National Cancer Institute·2026
Same author

Women's Conferences in Medicine: Advancing Gender Equity in Medical Education.

The clinical teacher·2026
Same author

Breast cancer risk-reducing medications - featuring the new kid, "baby tam".

Maturitas·2026
Same author

Performance of clinical breast cancer risk prediction models versus a mammography-based artificial intelligence risk model.

Journal of the National Cancer Institute·2026
Same author

Male breast health and breast cancer risk.

Maturitas·2026
Same author

Operating room communication and teamwork: An observational pilot study comparing objective and perceived collaboration.

Surgery·2026
Same journal

Thyroid Dysfunction and the Risk of Clinically Relevant Depression: A Longitudinal Cohort Study.

Mayo Clinic proceedings·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Bioidentical hormone therapy.

Julia A Files1, Marcia G Ko, Sandhya Pruthi

  • 1Division of Women's Health Internal Medicine, Mayo Clinic, 13400 E. Shea Blvd, Scottsdale, AZ 85259, USA. files.julia@mayo.edu

Mayo Clinic Proceedings
|May 3, 2011
PubMed
Summary
This summary is machine-generated.

Perimenopausal and menopausal symptoms can be treated with hormone therapy (HT). Compounded bioidentical HT is perceived as safer than FDA-approved HT, but requires careful physician management.

Related Experiment Videos

Last Updated: Jun 2, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Area of Science:

  • Reproductive Endocrinology
  • Women's Health
  • Pharmacology

Background:

  • Hormonal changes during perimenopause and menopause cause symptoms impacting quality of life.
  • Postmenopausal hormone therapy (HT) effectively treats these symptoms.
  • Concerns exist regarding health risks associated with certain combined HT formulations.

Purpose of the Study:

  • To define compounded bioidentical HT.
  • To compare compounded bioidentical HT with FDA-approved HT.
  • To review claims and management strategies for compounded bioidentical HT.

Main Methods:

  • Literature review and comparative analysis.
  • Examination of claims made by compounded bioidentical HT proponents.
  • Development of clinical management recommendations.

Main Results:

  • Compounded bioidentical HT is perceived as a safer alternative to conventional HT by some women.
  • Significant differences exist between compounded bioidentical HT and FDA-approved HT.
  • Evidence supporting the safety and efficacy of compounded bioidentical HT is limited.

Conclusions:

  • Physicians must be aware of the distinctions between compounded bioidentical HT and FDA-approved HT.
  • Careful patient selection and monitoring are crucial for women using compounded bioidentical HT.
  • Further research is needed to establish the safety and efficacy of compounded bioidentical HT.